ctDNA Monitoring for Small Cell Lung Cancer: Ready for Prime Time?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 37097069.
- Also identified by DOI 10.1158/1078-0432.CCR-23-0420 and PMC identifier 10330146.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Small cell lung cancer (SCLC) is the deadliest form of lung cancer and has few precision medicine approaches available. A recent study analyzed circulating tumor DNA (ctDNA) in 33 patients with extensive-stage SCLC and showed that ctDNA levels and response patterns correlate strongly with clinical response and survival outcomes. See related article by Sivapalan et al., p. 2310.
Medical subject headings
- Small Cell Lung Carcinoma
- Cell-Free Nucleic Acids
- Lung Neoplasms
- Circulating Tumor DNA